Displaying drugs 1 - 25 of 406 in total
| Name | Weight | Structure | Desription | Categories |
|---|---|---|---|---|
| Vonicog alfa | 20000000.0 |  | Vonicog alfa is indicated for the on-demand treatment and control of bleeding episodes in adults previously diagnosed with von Willebrand disease. Vonicog alfa contains only the vWF and thus, its... | Not Available |
| Botulinum toxin type A | 900000.0 C6760H10447N1743O2010S32 |  | A purified form of botulinum toxin type A used to block acetylcholine release in the treatment of chronic sialorrhea, muscle spasticity, and dystonia, as well as in cosmetic applications. | Acetylcholine Release Inhibitors / Botulinum Toxins / Botulinum Toxins, Type A / Neuromuscular Agents / Neuromuscular Blocking Agents / Neurotoxins |
| Antihemophilic factor human | 480000.0 |  | A Factor VIII replacement therapy used to treat hemophilia A. | Blood Coagulation Factors |
| Efanesoctocog alfa | 312000.0 |  | A recombinant DNA-derived, Factor VIII concentrate indicated for routine prophylaxis, on-demand treatment and control of bleeding episodes, and perioperative management of bleeding in patients with hemophilia A. | Amino Acids, Peptides, and Proteins / Biological Factors / Blood Coagulation Factors / Blood Proteins / Factor VIII / Hemostatics / Proteins / Recombinant Fusion Proteins / Recombinant Proteins |
| Rurioctocog alfa pegol | 269812.0 C12257H17863N3220O3552S83 | | A pegylated recombinant human coagulation factor VIII used to treat and prevent bleeding episodes in patients 12 years and above with hemophilia A. | Coagulants / Recombinant Proteins |
| Antihemophilic factor, human recombinant | 264725.5 C11794H18314N3220O3553S83 |  | A form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency. | Blood Coagulation Factors |
| Rilonacept | 251000.0 C9030H13932N2400O2670S74 | | An IL-1 inhibitor used to treat cryopyrin-associated periodic syndrome, a rare hereditary inflammatory disorder. | Interleukin Inhibitors |
| Efmoroctocog alfa | 220000.0 C9736H14863N2591O2855S78 | | A recombinant Factor VIII used to treat and prevent bleeding in hemophilia A. | Hemostatics / Human Antihemophilic Factors |
| Glofitamab | 194000.0 | | A bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma. | Amino Acids, Peptides, and Proteins / Antibodies / Antibodies, Monoclonal / Bispecific Monoclonal Antibodies / Blood Proteins / Globulins / Immunoglobulins / Immunoproteins / Proteins / Serum Globulins |
| Asfotase alfa | 180000.0 C7108H11008N1968O2206S56 |  | An enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP). | Enzyme Replacement Therapy / Enzymes / Tissue-nonspecific Alkaline Phosphatase |
| Moroctocog alfa | 173000.0 | | A recombinant Factor VIII used to treat hemophilia A to control bleeding. | Recombinant Proteins |
| Simoctocog alfa | 170000.0 | | An antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency). | Amino Acids, Peptides, and Proteins / Carbohydrates / Glycoconjugates / Proteins |
| Susoctocog alfa | 170000.0 | | A recombinant Factor VIII used to treat and prevent bleeding in hemophilia A. | Blood Coagulation Factors |
| Turoctocog alfa | 166000.0 C7480H11379N1999O2194S68 |  | An antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency). | Recombinant Proteins |
| Emapalumab | 154400.0 C6430H9898N1718O2038S46 | | An interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis. | Selective Immunosuppressants |
| Olaratumab | 154000.0 C6554H10076N1736O2048S40 | | A platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS). | Antibodies, Monoclonal |
| Tisotumab vedotin | 153000.0 | | A tissue factor-directed antibody drug conjugate that is used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. | Antineoplastic Agents, Immunological |
| Enfortumab vedotin | 152000.0 | | An antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer. | Amino Acids, Peptides, and Proteins / Antibodies / Antibodies, Monoclonal / Antibodies, Monoclonal, Humanized / Antibody-drug Conjugates / Antineoplastic Agents / Antineoplastic and Immunomodulating Agents / Blood Proteins / Cancer immunotherapy / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Globulins / Immunoglobulins / Immunoproteins / Immunotherapy / Microtubule Inhibitors / MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES / Nectin-4-directed Antibodies / P-glycoprotein substrates / Proteins / Serum Globulins |
| Cilgavimab | 152000.0 C6626H10218N1750O2078S44 | | An extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization. | Antiviral monoclonal antibodies |
| Gemtuzumab ozogamicin | 151500.0 |  | A monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia. | Antibodies, Monoclonal |
| Secukinumab | 151000.0 C6584H10134N1754O2042S44 |  | An immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders. | Interleukin Inhibitors |
| Loncastuximab tesirine | 151000.0 | | An antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas. | Antineoplastic Agents, Immunological |
| Botulinum toxin type B | 150804.0 |  | A purified form of botulinum toxin type B used to block acetylcholine release in the treatment of cervical dystonia and sialorrhea. | Acetylcholine Release Inhibitors / Anti-Dyskinesia Agents / Neurotoxins |
| Catumaxomab | 150511.0 |  | For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label]. | Gastrointestinal Agents |
| Brentuximab vedotin | 150500.0 C6476H9930N1690O2030S40 |  | A CD30-directed antibody-drug conjugate used to treat various types of lymphoma. | Antibodies, Monoclonal |
Displaying drugs 1 - 25 of 406 in total